Actuate Therapeutics’ Lock-Up Period To End on February 10th (NASDAQ:ACTU)

Actuate Therapeutics’ (NASDAQ:ACTU) lock-up period will expire on Monday, February 10th. Actuate Therapeutics had issued 2,800,000 shares in its initial public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Actuate Therapeutics Trading Down 6.6 %

Shares of Actuate Therapeutics stock opened at $8.82 on Friday. The firm has a 50-day moving average price of $8.48. Actuate Therapeutics has a 52-week low of $5.51 and a 52-week high of $11.73.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Freestone Capital Holdings LLC purchased a new stake in shares of Actuate Therapeutics during the fourth quarter valued at approximately $80,000. KG&L Capital Management LLC bought a new position in shares of Actuate Therapeutics during the third quarter valued at approximately $89,000. Sigma Planning Corp bought a new position in shares of Actuate Therapeutics during the fourth quarter valued at approximately $128,000. Finally, Northwestern University bought a new position in shares of Actuate Therapeutics during the third quarter valued at approximately $207,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.